New Treatment Approach for Difficult High Blood Pressure

A new experimental drug called Baxdrostat by AstraZeneca shows promise in treating resistant high blood pressure, especially for patients who do not respond well to existing medications. In a recent trial, Baxdrostat significantly lowered blood pressure in participants, potentially offering a new approach to reduce cardiovascular risks. The drug works by blocking aldosterone, a hormone that contributes to salt and water retention, and could become a key treatment for difficult-to-control hypertension if approved.